Discover
NGEN
NervGen Pharma Corp.
1.73
2 x 1.29
2 x 2.25
bid
ask
-
0.02
1.14%
2 @ 04:00 PM
1.73 +0.00 (0.00%)
| Ytd | -69.11% | |
| 1y | -48.05% |
1.71
day range
1.80
1.59
52 week range
5.97
| Open | 1.75 | Prev Close | 1.75 | Low | 1.71 | High | 1.80 | Mkt Cap | 186.01M |
| Vol | 293.22K | Avg Vol | 565.19K | EPS | -0.56 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-23 | 50-d Avg | 1.94 | 200-d Avg | 3.16 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 12.20M | ||
| Research and Development Expense | 7.89M | ||
| Selling, General and Administrative Expense | 4.31M | ||
| Operating Income | -12.20M | ||
| Net Income | -29.22M | ||
| Net Income Common Stock | -29.22M | ||
| Net Income Common Stock (USD) | -20.58M | ||
| Consolidated Income | -29.22M | ||
| Earnings per Basic Share | -0.32 | ||
| Earnings per Basic Share (USD) | -0.22 | ||
| Earnings per Diluted Share | -0.37 | ||
| Earning Before Interest & Taxes (EBIT) | -29.22M | ||
| Earning Before Interest & Taxes (USD) | -20.58M | ||
| Weighted Average Shares | 92.44M | ||
| Weighted Average Shares Diluted | 92.44M | ||
| Balance Sheet | |||
| Cash and Equivalents | 86.79M | ||
| Cash and Equivalents (USD) | 61.12M | ||
| Trade and Non-Trade Receivables | 200.24K | ||
| Current Assets | 89.81M | ||
| Total Assets | 90.19M | ||
| Current Liabilities | 72.91M | ||
| Total Liabilities | 72.91M | ||
| Accumulated Retained Earnings (Deficit) | -177.66M | ||
| Shareholders Equity | 17.28M | ||
| Shareholders Equity (USD) | 12.17M | ||
| Assets Non-Current | 381.27K | ||
| Goodwill and Intangible Assets | 381.27K | ||
| Trade and Non-Trade Payables | 4.29M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 13.95K | ||
| Net Cash Flow from Financing | 78.15M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 70.23M | ||
| Issuance (Purchase) of Equity Shares | 78.15M | ||
| Net Cash Flow from Operations | -5.73M | ||
| Effect of Exchange Rate Changes on Cash | -2.18M | ||
| Share Based Compensation | 2.74M | ||